Anaesthesia complication rates

Article

Anaesthesia administered by sharp needles carries a greater risk of serious complications than subtenons cannula administration, according to a study published online ahead of print in Eye.

Anaesthesia administered by sharp needles carries a greater risk of serious complications than subtenons cannula administration, according to a study published online ahead of print in Eye.

Rob L. Johnston of Gloucestershire Eye Department, Cheltenham General Hospital, UK and colleagues evaluated the Cataract National Dataset, which contains electronically recorded patient data gathered from 12 UK National Health Service Trusts.

An ophthalmologist administered anaesthetic in 56.7% of the 55 567 operations performed; anaesthetic was administered by an anaesthetist for 42.1% of operations, and by an assistant in 0.3% of the cases (personnel administering anaesthesia in the remaining 0.9% was unrecorded).

Across all Trusts, local anaesthesia was used in 95.5% of cases; topical anaesthesia, 22.3%; topical and intracameral, 4.7%; subtenons, 46.9%; peribulbar, 19.5%; retrobulbar, 0.5%. Minor complications (≥1) associated with sharp needle or subtenons cannula administration occurred in 4.3% of cases, with subtenons administration being 2.3 times more likely than sharp needles to cause minor complications. Serious complications associated with sharp needle or subtenons cannula administration occurred in 0.066% of cases (n=25), with sharp needle administration being 2.5 times more likely than subtenons to cause serious complications.

The team noted that, although subtenons administration of anaesthesia was associated with a greater risk of minor complications, sharp needles were more likely to produce serious complications.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.